Skip to content
Home/Companies/Biotech/Ablynx NV

Ablynx NV

Biotech·Belgium·Exited 2018·Held 10yr
Entry
2008
Hold
10yr
Exit
2018

Who owns Ablynx NV?

Ablynx NV is a Belgian Biotech company, now owned by Sanofi, which acquired it in 2018 from Sofinnova Partners.

Hand-verified · updated 2026-09-30

Open JSON · CC-BY
Sofinnova Partners
Investor
Sofinnova Partners
Sofinnova Capital VI · 2008 · Life Sciences VC

Key facts

HQBelgium
SectorBiotech
Exit Type
Trade Sale
Buyer
Sanofi
Exit Year
2018

More from Sofinnova Capital VI

Other portfolio companies in the same fund.

ABIONYX Pharma
Exited 2020
BiotechFrance· 2010
DBV
Exited 2014
BiotechFrance· 2010
Omthera Pharmaceuticals
Exited 2013
BiotechUS· 2010
to AstraZeneca
Addex Therapeutics
Exited 2012
BiotechSwitzerland· 2008
Movetis
Exited 2010
BiotechBelgium· 2008
to Shire
Noxxon Pharma
Exited 2016
BiotechGermany· 2008

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns Ablynx NV?

Ablynx NV is now owned by Sanofi, which acquired it in 2018 from Sofinnova Partners.

When did Sanofi acquire Ablynx NV?

Sanofi acquired Ablynx NV in 2018, buying from Sofinnova Partners.

Who did Ablynx NV sell to?

Sofinnova Partners sold Ablynx NV to Sanofi in 2018 (Trade Sale).

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue